How PX1 Tests Every CJC-1295 (No DAC) Lot (HPLC, MS, Endotoxin)
To ensure maximum assay reproducibility in laboratory settings, PX1 Research subjects every batch of CJC-1295 (No DAC) to a rigorous analytical testing battery. From reverse-phase HPLC purity profiling and mass spectrometry identity checks to LAL endotoxin quantitation, our USA-manufactured lot controls establish an uncompromising benchmark for preclinical research compounds.
Quick answer
To ensure maximum assay reproducibility in laboratory settings, PX1 Research subjects every batch of CJC-1295 (No DAC) to a rigorous analytical testing battery. From reverse-phase HPLC purity profiling and mass spectrometry identity checks to LAL endotoxin quantitation, our USA-manufactured lot controls establish an uncompromising benchmark for preclinical research compounds.
Key takeaways
- [CJC-1295](/research-peptides/cjc-1295-no-dac) without Drug Affinity Complex (DAC)—also commonly referred to as Modified GRF 1-29 or tetrasubstituted GRF 1-29—is a synthetic 29-amino acid peptide analog of endogenous Growth Hormone-Releasing Hormone (GHRH).
- The first pillar of PX1's analytical testing pipeline is high-resolution identity confirmation using Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) mass spectrometry.
- While mass spectrometry confirms identity, Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is the definitive analytical method used to quantify chemical purity.
- A common point of confusion in peptide research is the distinction between total gross weight and net peptide content.
Introduction to CJC-1295 (No DAC) Quality Standards in Laboratory Research
CJC-1295 without Drug Affinity Complex (DAC)—also commonly referred to as Modified GRF 1-29 or tetrasubstituted GRF 1-29—is a synthetic 29-amino acid peptide analog of endogenous Growth Hormone-Releasing Hormone (GHRH). In preclinical models, this compound acts as a selective GHRH receptor agonist. In vitro and animal studies indicate that CJC-1295 (No DAC) binds to GHRH receptors on anterior pituitary somatotrophs, triggering intracellular cAMP signaling cascades that stimulate pulsatile growth hormone (GH) secretion and downstream insulin-like growth factor 1 (IGF-1) expression evaluated in tissue repair models.
Because small structural modifications or trace impurities can dramatically alter receptor affinity, enzymatic half-life, or cellular response in vitro, acquiring cjc-1295 (no dac) third party tested material is critical for research integrity. PX1 Research enforces strict quality control standards across all synthesized lots. Our multi-stage analytical testing protocol guarantees that laboratories receive fully characterized, highly purified research compounds devoid of synthesis side-products, residual solvents, or biological contaminants.
By publishing lot-specific analytical data produced in ISO 17025 accredited testing facilities, PX1 provides researchers with transparent verification of peptide identity, purity, net content, and biological safety. This level of quality assurance ensures that observed experimental outcomes are directly attributable to the target peptide sequence rather than batch artifact contaminants.
Chemical Identity and Sequence Verification via Mass Spectrometry (MS)
The first pillar of PX1's analytical testing pipeline is high-resolution identity confirmation using Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) mass spectrometry. CJC-1295 (No DAC) possesses a chemical formula of C152H252N44O42 and a calculated theoretical monoisotopic mass of approximately 3367.97 Da (with a nominal molecular weight of 3297.8 Da depending on counter-ion adducts and salt state).
During mass spectrometric analysis, the sample is ionized, and the mass-to-charge ratio (m/z) of the resulting molecular ions is measured. The primary spectral peak must match the theoretical molecular weight of CJC-1295 (No DAC) within strict tolerance windows (typically ±1 Da). Mass spectrometry effectively rules out major sequence errors, such as missing amino acids (truncations), incomplete deprotection steps during solid-phase peptide synthesis (SPPS), or incorrect disulfide bonding/substitution patterns.
Investigators reviewing our published reports can inspect the full mass spectrum for each batch within our preclinical research library. The presence of a clean, sharp main ion signal corresponding to the target molecular weight confirms that the synthesized peptide contains the exact amino acid sequence required for GHRH receptor binding assays.
Purity Quantification: Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC)
While mass spectrometry confirms identity, Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is the definitive analytical method used to quantify chemical purity. HPLC separates the primary peptide from closely related synthesis impurities, such as deletion sequences, diastereomers, oxidized fragments, and trifluoroacetic acid (TFA) salt peaks.
PX1 utilizes hydrophobic C18 stationary phase columns with calibrated gradient elutions of acetonitrile and water supplemented with 0.1% TFA. Ultraviolet (UV) detection is monitored at a wavelength of 214 nm, corresponding to the peptide backbone absorption band. The purity of the batch is calculated using area-under-the-curve (AUC) integration, expressed as an RP-HPLC area percentage.
PX1 enforces a strict baseline threshold: every lot of CJC-1295 (No DAC) must demonstrate ≥98.0% HPLC area percent purity. Any batch displaying significant secondary peaks, baseline drift, or co-eluting impurites above 1.0% is rejected immediately. This ensures that researchers conducting sensitive cell culture or biochemical assays receive peptides free of competitive antagonists or inhibitory fragments.
Peptide Content vs. Gross Lyophilized Mass Analysis
A common point of confusion in peptide research is the distinction between total gross weight and net peptide content. Lyophilized peptide cakes contain not only the pure active peptide sequence, but also residual moisture (hydroscopic water) and counter-ions (typically acetate or trifluoroacetate salts) retained from the purification process. Consequently, a 5 mg vial of gross lyophilized powder does not equal 5 mg of pure peptide mass.
To provide full clarity for quantitative biochemical protocols, PX1 evaluates Net Peptide Content (also known as peptide purity factor) using Nitrogen Analysis (Elemental Analysis) or Quantitative Amino Acid Analysis (AAA). This determination establishes the exact ratio of pure peptide sequence mass relative to total dry powder weight, which typically ranges between 80% and 90% in high-grade lyophilized preparations.
Understanding net peptide content allows researchers to adjust molar concentration calculations accurately during reconstitution. When establishing precise stoichiometric working solutions for in vitro somatotroph receptor binding studies, referring to our batch-specific metrics ensures that test concentrations remain perfectly calibrated across experimental replicates.
Endotoxin Quantitation via Limulus Amebocyte Lysate (LAL) Testing
Bacterial endotoxins—lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative bacteria—pose a significant threat to cell culture assays and in vivo preclinical models. Even sub-nanogram quantities of endotoxin can trigger inflammatory cytokine cascades, alter intracellular signaling pathways, or cause cell death in vitro, leading to confounded experimental data.
PX1 subjects every production lot of CJC-1295 (No DAC) to quantitative kinetic chromogenic Limulus Amebocyte Lysate (LAL) testing in an ISO 17025 accredited laboratory environment. This assay measures the enzymatic reaction triggered by endotoxins in real time, yielding a precise measurement expressed in Endotoxin Units per milligram (EU/mg).
While standard industry thresholds often allow up to 10 EU/mg or more, PX1 sets an stringent internal specification threshold of <0.01 EU/mg to <0.05 EU/mg across our product line. By verifying exceptionally low endotoxin burden prior to distribution, PX1 protects research models against non-specific inflammatory signaling and cell toxicity.
Sterility Assays and Lyophilization Fill Consistency
In addition to chemical purity and endotoxin screening, physical fill consistency and sterility are essential for maintaining stable, uncompromised reagents. PX1 manufactures research peptides in cGMP-compliant facilities using ISO Class 5 cleanroom environments.
Prior to lyophilization, peptide solutions are passed through sterile 0.22-micron membrane filters to remove microbial contaminants. The bulk liquid is then precision-dispensed into borosilicate glass vials using automated gravimetric liquid handlers that maintain fill volume accuracy within strict ±1% tolerances. This guarantees that every vial within a given lot contains a uniform quantity of compound.
Representative samples from each production run undergo USP <71> compliant sterility testing, involving 14-day incubation in Fluid Thioglycollate Medium (FTM) and Soybean-Casein Digest Medium (SCDM) to confirm the complete absence of aerobic bacteria, anaerobic bacteria, and fungi. Vials are subsequently stoppered under vacuum with inert nitrogen gas and sealed with flip-off aluminum caps to prevent oxidation and moisture ingress during storage.
Retained Samples, Stability Testing, and Lot Continuity
Quality control does not end upon batch release. PX1 retains dedicated archival samples from every manufactured lot under controlled cryogenic (-80°C) and frozen (-20°C) conditions. These retained samples serve as reference standards for ongoing real-time and accelerated stability testing.
Through periodic re-analysis via RP-HPLC and MS, our laboratory evaluates thermal degradation kinetics, hydrolysis rates, and shelf-life stability under various environmental conditions. This rigorous stability monitoring ensures that our peptides maintain structural integrity throughout their shelf life when stored according to recommended laboratory guidelines.
Furthermore, maintaining retained samples allows PX1 to perform re-verification assays should a research group encounter anomalous baseline metrics during experimentation. If necessary, researchers can consult with our technical support team through wholesale research accounts for extended batch tracking and analytical verification data.
Comparative Analysis: CJC-1295 (No DAC) vs. CJC-1295 DAC and Sermorelin
When designing GHRH axis research protocols, investigators frequently compare CJC-1295 (No DAC) to structural alternatives and complementary secretagogues. Understanding these chemical differences aids in selecting the optimal test compound for specific research hypotheses.
For instance, CJC-1295 DAC incorporates a Lysine linker bound to a Maleimidopropionic acid Drug Affinity Complex group at the C-terminus. This modification enables irreversible covalent binding to circulating serum albumin in vivo, extending its biological half-life from approximately 30 minutes to over 6 to 8 days. In contrast, CJC-1295 (No DAC) lacks this complex, preserving a shorter half-life that allows researchers to study rapid, physiological GHRH receptor signaling pulses without long-term systemic receptor saturation.
Another relevant benchmark is Sermorelin, which represents the native 29-amino acid N-terminal sequence of GHRH (GRF 1-29). CJC-1295 (No DAC) replaces four specific amino acids (Ala2->D-Ala2, Gln8->Gln8, Asp11->Glu11, Leu15->Ala15) to enhance resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage. When paired with growth hormone secretagogues such as Ipamorelin, CJC-1295 (No DAC) demonstrates synergistic GH release in preclinical models due to dual stimulation of both GHRH and ghrelin/GHS-R1a receptor pathways.
Step-by-Step Guide: How to Match Your Vial Lot to the Official COA
To maintain absolute transparency, PX1 links every single vial distributed directly to its specific batch testing documentation. Researchers can verify their compound's identity and analytical purity prior to reconstitution by following a straightforward verification protocol.
First, locate the printed lot number printed directly on the label of your PX1 CJC-1295 (No DAC) vial. Next, navigate to the official PX1 Certificate of Analysis lookup portal on our website. Enter the exact alphanumeric lot code into the database search field.
The system will instantly display the lot-specific Certificate of Analysis PDF. Verify that the lot number on the document matches your physical vial, and inspect the raw RP-HPLC chromatogram (confirming >98% purity peak area), the mass spectrum (verifying the theoretical m/z peak at ~3367.9 Da), the LAL endotoxin test result (<0.05 EU/mg), and the net peptide content percentage. This process ensures complete traceable verification from synthesis to benchwork.
Reconstitution Protocols and Solvent Compatibility in the Laboratory
Proper reconstitution technique is critical to maintain peptide stability and prevent physical aggregation or enzymatic degradation once the lyophilized cake is solubilized. CJC-1295 (No DAC) should be reconstituted using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile Phosphate-Buffered Saline (PBS, pH 7.4) depending on the intended experimental assay.
Prior to diluent addition, allow the sealed vial to equilibrate to room temperature to prevent condensation inside the glass container. Inject the solvent gently along the inner glass wall of the vial rather than spraying directly onto the lyophilized powder mass. Swirl the vial gently with a smooth circular motion until completely dissolved; high-speed vortexing or vigorous shaking must be avoided as mechanical shear forces can denature peptide secondary structures.
To simplify molarity calculations and volume planning across various vial sizes, researchers can utilize the PX1 interactive reconstitution calculator. For broader research requirements, explore our comprehensive catalog of all peptides to source fully verified, USA-manufactured research compounds.
Frequently Asked Questions
How do I verify that my batch of CJC-1295 (No DAC) is third party tested?
Every batch of CJC-1295 (No DAC) from PX1 includes a unique lot number printed on the vial label. You can cross-reference this lot number in our online Certificate of Analysis portal to access full HPLC chromatograms, mass spectrometry reports, and LAL endotoxin testing results from independent ISO 17025 accredited laboratories.
What is the acceptable endotoxin limit for PX1 research peptides?
PX1 enforces an internal specification limit of <0.01 EU/mg to <0.05 EU/mg for all research peptides, measured via kinetic chromogenic LAL testing. This strict threshold minimizes inflammatory artifacts in cell cultures and preclinical animal models.
Why is Net Peptide Content important compared to gross mass?
Lyophilized peptide powder contains counter-ions (such as acetate or TFA) and bound residual moisture. Net Peptide Content measures the actual percentage of active peptide mass within the lyophilized cake (typically 80-90%), allowing researchers to calculate exact molar concentrations for quantitative in vitro experiments.
What is the primary structural difference between CJC-1295 with DAC and CJC-1295 without DAC?
CJC-1295 with DAC includes a Drug Affinity Complex modification that allows it to bind covalently to serum albumin, extending its biological half-life to several days. CJC-1295 without DAC (Modified GRF 1-29) lacks this complex, exhibiting a shorter half-life (~30 minutes) ideal for studying acute, pulsatile GHRH signaling.
How should lyophilized CJC-1295 (No DAC) be stored in the laboratory?
Lyophilized CJC-1295 (No DAC) should be stored at -20°C for short-to-medium term storage, or at -80°C for long-term storage, protected from light and desiccation. Reconstituted liquid solutions should be kept refrigerated at 2°C to 8°C and used within 14 to 30 days depending on the bacteriostatic preservative used.
How do I calculate laboratory solvent volumes for reconstitution?
You can use the PX1 online reconstitution calculator to determine exact diluent volumes based on vial mass (e.g., 2 mg or 5 mg) and desired working concentration (e.g., mcg/mL or micromolar) for your specific assay protocol.
What analytical methods does PX1 use to test CJC-1295 (No DAC)?
PX1 utilizes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity determination, Mass Spectrometry (ESI-MS or MALDI-TOF) for sequence/identity verification, kinetic chromogenic LAL assays for endotoxin quantitation, and USP <71> methods for fill sterility.
Are PX1 research peptides intended for human consumption or clinical use?
No. All compounds supplied by PX1 Research are strictly for laboratory in vitro and preclinical research use only. They are not intended for human or veterinary use, medical treatment, or clinical administration.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.